Pharma News

The coronavirus pandemic interrupted efforts to control malaria, resulting in 63,000 additional deaths and 13 million more infections globally over two years, according to a report from the World H...

The FDA has granted a priority review to Pfizer’s Biologics License Application for its vaccine candidate RSVpreF for respiratory syncytial virus (RSV)-associated lower respiratory tract disease ...

In the United States, Orphan Drug designation is granted to drugs or biologics intended to treat, diagnose, or prevent rare diseases or conditions. 

Olutasidenib (Rezlidhia) is indicated for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation detected by an FDA-approved test. ...

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies ...

The FDA has approved Ferring Pharmaceuticals’ fecal transplant therapy Rebyota for the prevention of recurrence of C. difficile infection (CDI) in individuals that have completed antibiotic trea...

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

X4 Pharmaceuticals has announced positive top-line results from a Phase 3 study of its lead investigational therapy, mavorixafor, in people with warts, hypogammaglobulinemia, infections, and myelok...

ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Na...

The FDA has issued a warning letter to a Lake Forest, Calif.-based biologics company, Invitrx Therapeutics, for selling unapproved allogenic cellular-derived drugs, including a human umbilical cord...

Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) in combination with docetaxel has received marketing authorization from the UK’s Medicines and Healthcare products Regulato...

Full-Life Technologies, a radiotherapeutics company, has entered into an agreement to acquire Focus-X Therapeutics and its cancer-targeting radiopharmaceuticals. ...